The observation that RyR2 inhibition equips Tconvs with suppressive function (albeit with more limited capacity than Tregs in vivo) opens new opportunities for therapeutic targeting of the RyR2 pathway to heighten Tconv suppressive function in autoimmune diseases and graft-versus-host disease. Here, RYR2 is linked to autoimmune disease.